1. Home
  2. CADL vs SIGIP Comparison

CADL vs SIGIP Comparison

Compare CADL & SIGIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

N/A

Current Price

$11.27

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Logo Selective Insurance Group Inc. Depositary Shares each representing a 1/1000th interest in a share of 4.60% Non-Cumulative Preferred Stock Series B

SIGIP

Selective Insurance Group Inc. Depositary Shares each representing a 1/1000th interest in a share of 4.60% Non-Cumulative Preferred Stock Series B

N/A

Current Price

$15.20

Market Cap

0.0

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CADL
SIGIP
Founded
1999
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
N/A
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
CADL
SIGIP
Price
$11.27
$15.20
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$19.00
N/A
AVG Volume (30 Days)
1.2M
4.5K
Earning Date
05-14-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
58.62
131.89
EPS
N/A
3.69
Revenue
$125,000.00
$5,336,928,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$4.08
Revenue Growth
N/A
9.78
52 Week Low
$4.35
$15.20
52 Week High
$14.00
$18.71

Technical Indicators

Market Signals
Indicator
CADL
SIGIP
Relative Strength Index (RSI) 43.88 41.06
Support Level $4.91 $15.20
Resistance Level $11.36 $16.05
Average True Range (ATR) 0.70 0.21
MACD -0.34 -0.02
Stochastic Oscillator 31.85 44.25

Price Performance

Historical Comparison
CADL
SIGIP

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

About SIGIP Selective Insurance Group Inc. Depositary Shares each representing a 1/1000th interest in a share of 4.60% Non-Cumulative Preferred Stock Series B

Selective Insurance Group Inc is a regional property-casualty insurer based in New Jersey, with its operations focused in the New York metropolitan area. The Company has four operating segments: Standard Commercial Lines, Standard Personal Lines, E&S Lines, and Investments. Majority of revenue is gained from Standard Commercial Lines segment, which comprises of property and casualty insurance products and services provided in the standard marketplace to commercial enterprises, which are typically businesses, non-profit organizations, and local government agencies.

Share on Social Networks: